BIND Therapeutics, Inc. (NASDAQ: BIND) is a clinical-stage nanomedicine company developing a pipeline of ACCURINS®, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. The company is leveraging its Medicinal Nanoengineering® platform to develop its pipeline of ACCURINS targeting hematological and solid tumors, and has a number of strategic collaborations with biopharmaceutical companies to develop ACCURINS in areas of high unmet need. For more information, visit the company’s website at www.bindtherapeutics.com